Switching to generics: always a cost‐effective option?
Authors
Abstract
Dr Solanki provides three case studies where patients were switched to generic alendronic acid to demonstrate that switching programmes can be unsafe and prove a false economy Copyright © 2008 Wiley Interface Ltd
Digital Object Identifier (DOI)
10.1002/psb.274 About DOI
Login/Logout
Journal Menu
- Home
- News
- Current Issue
- Archive Issues
- Learning Central
- Ask Prescriber
- Prescriber Blog
- Forthcoming Events
- Supplements
- Wiley Job Network
Advertising and Sponsorship
Other Journals
